|
|
Blood, 15 December 2005, Vol. 106, No. 13, pp. 4043-4049.
Prepublished online as a Blood First Edition Paper on August 18, 2005; DOI 10.1182/blood-2003-10-3446.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study
James A. Whitlock,
Harland N. Sather,
Paul Gaynon,
Leslie L. Robison,
Robert J. Wells,
Michael Trigg,
Nyla A. Heerema, and
Smita Bhatia
From the Department of Pediatric Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN; Children's Oncology Group, Arcadia, CA; Children's Center for Cancer and Blood Diseases, Children's Hospital, Los Angeles, CA; Division of Epidemiology/Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis; Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX; Division of Blood and Bone Marrow Transplantation, Alfred I. du Pont Hospital for Children, Wilmington, DE; Department of Cytogenetics, Children's Hospital of Columbus, OH; and Division of Pediatrics, City of Hope Cancer Center, Duarte, CA.
We assessed the outcome of children with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) receiving contemporary risk-based therapy by evaluating clinical and biologic features and outcome of children with ALL, with or without DS, enrolled in Children's Cancer Group (CCG) protocols between 1983 and 1995. Comparison of characteristics of children with ALL with (ALL-DS; n = 179) or without (ALL-NDS; n = 8268) DS showed no differences in initial white blood cell (WBC) count, central nervous system disease, and risk group. Children with ALL-DS did not present with unfavorable translocations and were older than 1 year of age at diagnosis with ALL. Event-free (56% vs 74%; P < .001) and disease-free (55% vs 73%; P < .001) survival at 10 years was significantly lower in the standard-risk ALL-DS population compared with ALL-NDS, but not in high-risk ALL-DS population (event-free survival, 62% vs 59%; P = .9; disease-free survival, 64% vs 59%; P = .9), and these differences persisted regardless of treatment era (early era [1983-1989] vs recent era [1989-1995]). Multivariate analysis revealed that presence of DS demonstrated an independent significant adverse prognostic effect for the standard-risk population, but not for the high-risk patients. These results suggest that intensification of therapy for patients with ALL-DS is needed to maintain outcome comparable with those of ALL-NDS patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
ALL in children with Down syndrome
- Franklin O. Smith
Blood 2005 106: 4018.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
I. Ganmore, G. Smooha, and S. Izraeli
Constitutional aneuploidy and cancer predisposition
Hum. Mol. Genet.,
April 15, 2009;
18(R1):
R84 - R93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Malinge, S. Izraeli, and J. D. Crispino
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome
Blood,
March 19, 2009;
113(12):
2619 - 2628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Rabin and J. A. Whitlock
Malignancy in Children with Trisomy 21
Oncologist,
February 1, 2009;
14(2):
164 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kearney, D. Gonzalez De Castro, J. Yeung, J. Procter, S. W. Horsley, M. Eguchi-Ishimae, C. M. Bateman, K. Anderson, T. Chaplin, B. D. Young, et al.
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia
Blood,
January 15, 2009;
113(3):
646 - 648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Forestier, S. Izraeli, B. Beverloo, O. Haas, A. Pession, K. Michalova, B. Stark, C. J. Harrison, A. Teigler-Schlegel, and B. Johansson
Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study
Blood,
February 1, 2008;
111(3):
1575 - 1583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Webb, I. Roberts, and P. Vyas
Haematology of Down syndrome
Arch. Dis. Child. Fetal Neonatal Ed.,
November 1, 2007;
92(6):
F503 - F507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Linabery, A. F. Olshan, A. S. Gamis, F. O. Smith, N. A. Heerema, C. K. Blair, and J. A. Ross
Exposure to Medical Test Irradiation and Acute Leukemia Among Children With Down Syndrome: A Report From the Children's Oncology Group
Pediatrics,
November 1, 2006;
118(5):
e1499 - e1508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
